Viral Clearance

Global Viral Clearance Market to Reach US$2.0 Billion by 2030

The global market for Viral Clearance estimated at US$749.0 Million in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 18.2% over the analysis period 2024-2030. Recombinant Proteins, one of the segments analyzed in the report, is expected to record a 18.5% CAGR and reach US$467.7 Million by the end of the analysis period. Growth in the Blood and Blood Products segment is estimated at 15.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$215.9 Million While China is Forecast to Grow at 17.8% CAGR

The Viral Clearance market in the U.S. is estimated at US$215.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$319.2 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.0% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.5% CAGR.

Global Viral Clearance Market - Key Trends & Drivers Summarized

Why Is Viral Clearance Critical for Biopharmaceutical Safety?
Viral clearance has become an essential component in the development and manufacturing of biologics, ensuring the removal of potential viral contaminants from biopharmaceutical products. The rise in monoclonal antibodies, recombinant proteins, and gene therapy products has significantly increased the focus on stringent viral safety protocols. Regulatory agencies such as the FDA and EMA mandate comprehensive viral clearance studies to validate manufacturing processes, driving demand for advanced viral inactivation and removal technologies. Biopharmaceutical companies are increasingly investing in viral clearance solutions, including filtration, chromatography, and chemical inactivation, to meet these regulatory requirements and ensure product safety.

How Are Technological Innovations Transforming Viral Clearance Methods?
The market is witnessing a surge in technological innovations aimed at improving the efficiency and reliability of viral clearance. Advances in high-throughput screening, automation, and AI-driven analytics are streamlining viral clearance processes, reducing turnaround times, and enhancing accuracy. Novel filtration techniques, including nanofiltration and membrane chromatography, are gaining traction for their superior viral removal capabilities. The growing adoption of single-use bioprocessing systems has also necessitated the development of compatible viral clearance solutions, ensuring seamless integration into modern manufacturing workflows. Additionally, the increasing role of continuous bioprocessing is driving the need for real-time viral clearance monitoring and validation technologies.

What Market Dynamics Are Influencing the Growth of Viral Clearance Services?
The demand for viral clearance services is expanding as pharmaceutical companies increasingly outsource biologics manufacturing to contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The growing complexity of biologic drugs, coupled with stringent regulatory oversight, has led to an increase in specialized viral clearance testing services. The emergence of new biotherapeutics, including cell and gene therapies, has further intensified the need for reliable and scalable viral safety solutions. Additionally, the expanding vaccine development landscape, particularly in response to global health crises, is reinforcing the necessity of robust viral clearance strategies to ensure the safety and efficacy of immunotherapies.

The growth in the viral clearance market is driven by several factors, including the increasing number of biologics in the drug pipeline, advancements in viral removal technologies, and the rising outsourcing of biopharmaceutical manufacturing. The surge in gene and cell therapy development is further accelerating demand for comprehensive viral safety solutions. Additionally, the integration of AI and machine learning in viral clearance testing is enhancing process efficiency and regulatory compliance. The increasing adoption of single-use and continuous bioprocessing systems is also influencing market dynamics, necessitating innovative viral inactivation and filtration techniques. As regulatory standards continue to evolve, biopharmaceutical companies are investing in state-of-the-art viral clearance platforms to ensure product safety and expedite market approvals, driving sustained market growth.

SCOPE OF STUDY:

The report analyzes the Viral Clearance market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Application (Recombinant Proteins, Blood and Blood Products, Vaccines, Other Applications); End-Use (Pharmaceutical & Biotechnology, CROs, Academic Research Institutes, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• Avance Biosciences Inc.
• BSL BIOSERVICE Scientific Laboratories Munich GmbH
• Charles River Laboratories International, Inc.
• Clean Cells Inc.
• Lonza Group AG
• Merck KgaA
• SGS SA
• Sigma-Aldrich Corporation
• Texcell, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.